期刊
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
卷 39, 期 7, 页码 E370-E372出版社
LIPPINCOTT WILLIAMS & WILKINS
关键词
secondary AML; ewing sarcoma; leukapheresis; KRAS; BRAF
资金
- NCI NIH HHS [P30 CA086862] Funding Source: Medline
Ewing sarcoma is a pediatric bone and soft tissue sarcoma that requires intensive therapy, which can cause secondary malignancies. We present a rare case of early, treatment-related AML in a pediatric patient concurrently receiving primary therapy for Ewing sarcoma. Despite AML-directed therapy, our patient died secondary to complications of hyperleukocytosis. Cytogenetic and mutation profiling of the leukemia cells revealed the DNA-topoisomerase-II-inhibitor-associated t(9;11)(p22;q23) translocation and clonal KRAS and BRAF mutations. This report highlights the importance of monitoring for treatment-related effects in cancer therapy, as well as the need for novel, less toxic approaches in Ewing sarcoma therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据